Retatrutide vs HGH Fragment 176-191
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: LY3437943, Triple G
A triple agonist targeting GLP-1, GIP, and glucagon receptors. Phase 3 trials show up to 28.7% weight loss (71 lbs average), the highest of any obesity drug. Expected FDA approval late 2026 to early 2027.
Also: Frag 176-191, HGH Frag
The lipolytic fragment of human growth hormone. Contains the fat-burning portion of HGH without effects on blood sugar or cell proliferation.
Key Comparison Insights
- Both peptides belong to the Weight Loss category, suggesting similar primary applications.
Detailed Comparison
| Attribute | Retatrutide | HGH Fragment 176-191 |
|---|---|---|
| Category | Weight Loss | Weight Loss |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Retatrutide activates three receptors: GLP-1 for appetite suppression and glucose control, GIP for enhanced insulin response and metabolic effects, and glucagon for increased energy expenditure and fat oxidation. The triple mechanism provides synergistic effects. | Fragment 176-191 mimics the way natural HGH regulates fat metabolism but without adverse effects on blood sugar or growth. It stimulates lipolysis and inhibits lipogenesis, specifically targeting adipose tissue. |
| Common Dosing | 4-12 mg weekly Once weekly, same day each week | 250-500 mcg daily 1-2x daily, fasted |
| Administration | Subcutaneous injection weekly | Subcutaneous injection on empty stomach |
| Typical Duration | Long-term use expected | 8-12 weeks |
| Best Time to Take | Morning, same day each week | Before bed or morning (fasted) |
Possible Side Effects May vary by individual |
|
|
| Research Summary | Phase 3 TRIUMPH-4 trial (Dec 2025) showed 28.7% weight loss at 68 weeks, with average loss of 71 lbs. Also showed significant osteoarthritis pain relief, reduced cardiovascular risk markers, and 14 mmHg blood pressure reduction. Seven more Phase 3 readouts expected in 2026. NDA submission expected late 2025/early 2026. | Studies show enhanced fat loss, particularly in abdominal area. Research demonstrates no impact on glucose metabolism or IGF-1 levels. Works synergistically with diet and exercise for body composition improvement. |
Frequently Asked Questions: Retatrutide vs HGH Fragment 176-191
What is the difference between Retatrutide and HGH Fragment 176-191?
Retatrutide is a weight loss peptide that a triple agonist targeting glp-1, gip, and glucagon receptors. phase 3 trials show up to 28.7% weight loss (71 lbs average), the highest of any obesity drug. expected fda approval late 2026 to early 2027. HGH Fragment 176-191 is a weight loss peptide that the lipolytic fragment of human growth hormone. contains the fat-burning portion of hgh without effects on blood sugar or cell proliferation. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Retatrutide or HGH Fragment 176-191?
Neither is universally "better" - the choice depends on your specific goals. Retatrutide is typically used for weight loss purposes, while HGH Fragment 176-191 is used for weight loss. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Retatrutide and HGH Fragment 176-191 be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Retatrutide and HGH Fragment 176-191 together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.
Related Comparisons
View Full Peptide Profiles
Educational Information Only
This comparison of Retatrutide and HGH Fragment 176-191 is for educational purposes only. Neither this comparison nor any information on this site constitutes medical advice. Always consult with qualified healthcare providers before making decisions about peptides or other substances.